1353006-50-4 Usage
General Description
(S)-1-(3,5-Dimethoxyphenyl)ethanamine hydrochloride is a chemical compound that belongs to the class of phenethylamine derivatives. It is a psychoactive substance and a known hallucinogen, with effects similar to those of other compounds in the phenethylamine family, such as mescaline and 2C-I. (S)-1-(3,5-Dimethoxyphenyl)ethanamine hydrochloride is commonly referred to as 2C-H and has been used both recreationally and in research settings, where it is sometimes used as a reference standard for other psychoactive substances. Its effects include visual and auditory hallucinations, altered perception, and potential changes in mood and cognition. However, like other psychoactive substances, it carries potential risks and side effects, and its use is not without legal and health-related concerns.
Check Digit Verification of cas no
The CAS Registry Mumber 1353006-50-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,3,0,0 and 6 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1353006-50:
(9*1)+(8*3)+(7*5)+(6*3)+(5*0)+(4*0)+(3*6)+(2*5)+(1*0)=114
114 % 10 = 4
So 1353006-50-4 is a valid CAS Registry Number.
1353006-50-4Relevant articles and documents
N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG
-
Page/Page column 182, (2012/12/14)
The invention provides molecular entities that bind with high affinity to PPARG (PPAR3), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.
